Atheroma; Carotid ArteryCAPGADNCT07364058
Assessment of Platelet-derived GARP in Atherosclerotic Disease
An observational study of Atheroma; Carotid Artery and Atheromatosis, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atheroma; Carotid Artery, Atheromatosis
- What is being tested?
- Tissue sample and data collection
- How many people
- 200 participants
- Where
- 1 siteBelgium
- Study dates
- Feb 2026to Jan 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.
Who may be able to join
- Older than 18 years
- Able to give informed consent
- Undergoing carotid or femoral endarterectomy
Who cannot join
- Younger than 18 years
- Pregnant
- Dialysis
- Unable to give informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site
Cliniques Universitaires Saint-Luc
Brussels, 1200
Louis Charki, Medical Degree, +3224362014, louis.charki@uclouvain.be
Christophe Beauloye, Medical Degree
About this study
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
- Conditions
- Atheroma; Carotid Artery, Atheromatosis
- Being tested
- Tissue sample and data collection
- Keywords
- Atheroma, Atherosclerosis, GARP, LRRC32
- Medical subject headings
- Carotid Artery Diseases, Atherosclerosis, Plaque, Atherosclerotic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tissue sample and data collectionOther
Tissue sample and data collection
| Study group | Role | What they receive |
|---|---|---|
| Endarterectomy population | This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy. Receives: Other: Tissue sample and data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
GARP Expression in Platelets
The number of cells/area expressing the GARP protein will be assessed
Measured: Throughout the entire study, approximately during 3 years
Secondary outcomes (2)
GARP Expression T Regulating Cells
The number of cells expressing GARP will be assessed as a number of cells / area
Measured: Throughout the entire study, approximately during 3 years
GARP Expression General
The type of cells expressing GARP will be assessed as a number of cells / area
Measured: Throughout the entire study, approximately during 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study startFeb 2026 (estimated)
- Primary completionJan 2029 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atheroma; Carotid ArteryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Responsible party
- Sponsor
- Investigators
- Christophe Beauloye, Medical Degree, Principal investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07364058
- Sponsor's protocol ID
- CAPGAD
- Acronym
- CAPGAD
- Status last verified
- Jan 2026
- First submitted
- 15 Jan 2026
- Last updated
- 27 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No